ãã«ãããžã³ã®ïŒå¹Žéã®èª¿æ»çµæ
以åããã¡ãã®ããã°ïŒäžèšåç §ïŒã§ããžã¹ãããžã¢ã®è¬ãšããŠãã«ãããžã³ã玹ä»ãããšæããŸããæ¥æ¬ã§ã¯ãŸã èªå¯ãããŠããªããã䜿ãããŠããŸããããã¢ã¡ãªã«ã§ã¯èªå¯ãåŸãããŠããŸãã
ãããªäžããã«ãããžã³ã®ïŒå¹Žéã®äœ¿çšèª¿æ»çµæãå ±åãããŸããããã¡ãã¯ãå»åŠè«æãšããŠçºè¡šãããŠããŸãã
åŒçšæç®ïŒFactor SA, et al. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. J Clin Psychiatry. 2017. ãã«ãããžã³ãæäžããã人ãã¡ãæã€å ã ã®ç²Ÿç¥çŸæ£ã¯ãçµ±å倱調çããã€ç ãå極æ§é害ãªã©ã§ããããããç æ°ã«æ粟ç¥ç è¬ãšããè³ã®ãããã³ããããã¯ããè¬ã䜿ãããŸãããç¹ã«å€ãã¿ã€ãã®æ粟ç¥ç è¬ãé·æé飲ããšããžã¹ãããžã¢ãšããå£ãèãåæã«åããŠããŸãå¯äœçšãåºãããšããããŸãããã°ããããŠããåºçŸããã®ã§é çºæ§ãžã¹ãããžã¢ãšãåŒã°ããŸããæ®å¿µãªããããã®ãžã¹ãããžã¢ãšããå¯äœçšã¯æ²»ãã«ããã®ã§ãã ãã£ãšãžã¹ãããžã¢ã®è¬ã¯ç¡ãã£ãã®ã§ãããæè¿ã«ãªããã«ãããžã³ãšããè¬ãéçºãããŸãããåŒçšãã調æ»å ±åïŒäžèšïŒã«ã¯198人ã®ããŒã¿ãå ¥ã£ãŠããŸãããã®ãã¡ãçŽ6å²ã®æ¹ã§äžå¹Žéã®èª¿æ»ãå®äºããŸãããæ¹æ³ãšããŠã¯ã48é±éã«ããã£ãŠãã«ãããžã³ã䜿ããæåŸã®4é±éããããŠäžæ¢ãããšããæµãã§ãããã«ãããžã³ã䜿ã£ãŠããéã«ãã¢ã«ã·ãžã¢ïŒè¶³ããããããããããããçç¶ã§æ粟ç¥ç è¬ã®å¯äœçšã§ãïŒãããŒãã³ãœããºã ïŒããŒãã³ãœã³ç ã®ããã«äœãåãã«ãããªãçç¶ã®ããšã§ãæ粟ç¥ç è¬ã®å¯äœçšãšããŠããåºçŸããŸãïŒãšãã£ãå¯äœçšãåºãããšã¯ãªããèªæ®ºããããªããªã©ã®ç²Ÿç¥çãªåé¡ããããŸããã§ããããžã¹ãããžã¢ãžã®å¹æã¯äžå¹Žéç¶ããããã§ãã ã€ãŸãããã«ãããžã³ã¯äžå¹Žé䜿ã£ãŠã倧ããªåé¡ã¯ãªããå¹æãæç¶ãããšããçµæã§ããããšãŠã奜ãŸããçµæã§è¯ãã£ãã§ãããæ¥æ¬ã§ã®çºå£²ã«ãæåŸ ããããšããã§ãã